drugset / Trial / NCT02275598
Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma
Phase 2
Unknown
12 enrolled
University of Modena and Reggio Emilia
Millennium Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of two three-weekly 1.8 mg/kg Brentuximab vedotin administrations in untreated patients with Hodgkin Lymphoma (HL).
Timeline
- Start
- 2013-04
- Primary completion
- 2013-11
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brentuximab Vedotin | Monoclonal antibody | 1.8 mg/kg | Intravenous |
| Background | Bleomycin | Unknown | 10000 unknown | Intravenous |
| Background | Dacarbazine | Small molecule | 375 mg/m2 | Intravenous |
| Background | Doxorubicin | Other / unclassified | 25 mg/m2 | Intravenous |
| Background | Vinblastine | Small molecule | 6 mg/m2 | Intravenous |